Value | Category | Cases | |
---|---|---|---|
1 | Astrazeneca | 9 |
4.7%
|
2 | No sé | 66 |
34.2%
|
3 | Pfizer | 23 |
11.9%
|
4 | Sinopharm | 16 |
8.3%
|
Missing value | 79 |
40.9%
|